got in today good luck and mark this post $150's.
in and holding
January 6, 2014
See The Ratings Game for highlights.
Date Symbol Company Category
1/06/2014 GNW Genworth Financial Inc. Cl A
1/06/2014 ATHM Autohome Inc. ADS
1/06/2014 MET MetLife Inc.
1/06/2014 IDIX Idenix Pharmaceuticals Inc.
1/06/2014 WNC Wabash National Corp.
1/06/2014 VRTX Vertex Pharmaceuticals Inc.
1/06/2014 VLP Valero Energy Partners LP
1/06/2014 TSL Trina Solar Ltd. ADS
1/06/2014 JKS JinkoSolar Holding Co. Ltd. ADS
1/06/2014 RMAX RE/MAX Holdings Inc. Cl A
1/06/2014 DOC Physicians Realty Trust
1/06/2014 WYNN Wynn Resorts Ltd.
1/06/2014 WYNMF Wynn Macau Ltd.
1/06/2014 ARIA Ariad Pharmaceuticals Inc.
1/06/2014 ACOR Acorda Therapeutics Inc.
1/06/2014 SRPT Sarepta Therapeutics Inc.
1/06/2014 HFC HollyFrontier Corp.
-0.39 Rec-Downgrade 1/06/2014 MGM MGM Resorts International
By: Tom Meyer
12/27/2013 @ 12:22PM |405 views
The Race To Develop A Brain Cancer Treatment Takes An Interesting Turn
Given the remarkable results that aldoxorubicin demonstrated in 1st-Line STS, it’s hard not to believe that something similar could be in store for the Phase 2 GBM trial. CytRx certainly appears poised for a significant run in the months and years ahead as the company’s platform continues to be validated by science. But before taking a position, investors should take a look at the company’s finances as well.
As of the end of the third quarter, CytRx had approximately $23 million in available cash and short-term investments. That amount does not include the $25.9 million (less fees) that the company raised from its October offering. Given the company’s monthly burn rate of about $2 million, the company’s cash balance should be sufficient to fund operating expenses well into 2015 (at a minimum). CytRx Corporation appearsto be an extremely compelling investment story and investors may want to consider taking a position before the share price really starts to take off